Matches in SemOpenAlex for { <https://semopenalex.org/work/W1552004257> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1552004257 endingPage "428" @default.
- W1552004257 startingPage "410" @default.
- W1552004257 abstract "Recombinant adeno-associated viral (rAAV) vectors are safer and more effective than other in vivo gene delivery methods. Stereotaxic injection of the vectors provides continuous and selective expression of therapeutic proteins throughout the target area in primate brains without toxicity. Three phase I clinical trials for gene therapy for Parkinson's disease (PD) using rAAV vectors are currently underway. One trial involves gene transfer of aromatic L-amino acid decarboxylase (AADC), an enzyme that converts L-dopa to dopamine, to restore therapeutic windows of orally administered L-dopa in advanced idiopathic PD. After AADC transduction, the daily required dose of L-dopa can be reduced and the duration of the ON period is prolonged. Another trial involves transduction of the subthalamic nucleus (STN) with rAAV vectors expressing glutamic acid decarboxylases, a rate-limiting enzyme for synthesizing inhibitory the neurotransmitter gamma-aminobutyric acid (GABA). This strategy, which is similar to deep brain stimulation, aims at modulating hyperactive STN neurons, thereby alter the resulting activity of down-stream targets, which influence movement. However, the mechanism of stimulation remains unknown, and there are some theoretical concerns of chemical alteration. The other trial involves delivery of rAAV vectors expressing neurturin, a natural analog of a glial cell line-derived neurotrophic factor, into the putamen to slow down the ongoing degeneration of nigral dopaminergic neurons. Positron emission tomography with various tracers has been used to monitor the effects of therapeutic gene expression in vivo. Although no serious adverse effects of gene transfer have been reported so far in these trials, vector systems that regulate transgene expression are necessary to increase safety, and the development of such systems is in progress. Gene therapy using rAAV vectors may be a promising option for treatment of PD in the near future." @default.
- W1552004257 created "2016-06-24" @default.
- W1552004257 creator A5017641271 @default.
- W1552004257 date "2003-01-31" @default.
- W1552004257 modified "2023-10-16" @default.
- W1552004257 title "Gene Therapy for Parkinson’s Disease" @default.
- W1552004257 cites W977003153 @default.
- W1552004257 doi "https://doi.org/10.1201/b15280-17" @default.
- W1552004257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17447529" @default.
- W1552004257 hasPublicationYear "2003" @default.
- W1552004257 type Work @default.
- W1552004257 sameAs 1552004257 @default.
- W1552004257 citedByCount "1" @default.
- W1552004257 crossrefType "book-chapter" @default.
- W1552004257 hasAuthorship W1552004257A5017641271 @default.
- W1552004257 hasConcept C104317684 @default.
- W1552004257 hasConcept C111599444 @default.
- W1552004257 hasConcept C126322002 @default.
- W1552004257 hasConcept C137183658 @default.
- W1552004257 hasConcept C15152581 @default.
- W1552004257 hasConcept C160539049 @default.
- W1552004257 hasConcept C169760540 @default.
- W1552004257 hasConcept C170493617 @default.
- W1552004257 hasConcept C185856081 @default.
- W1552004257 hasConcept C2777319143 @default.
- W1552004257 hasConcept C2778107364 @default.
- W1552004257 hasConcept C2778542668 @default.
- W1552004257 hasConcept C2779134260 @default.
- W1552004257 hasConcept C2779734285 @default.
- W1552004257 hasConcept C40767141 @default.
- W1552004257 hasConcept C513476851 @default.
- W1552004257 hasConcept C55493867 @default.
- W1552004257 hasConcept C71924100 @default.
- W1552004257 hasConcept C86803240 @default.
- W1552004257 hasConcept C92087593 @default.
- W1552004257 hasConcept C98274493 @default.
- W1552004257 hasConceptScore W1552004257C104317684 @default.
- W1552004257 hasConceptScore W1552004257C111599444 @default.
- W1552004257 hasConceptScore W1552004257C126322002 @default.
- W1552004257 hasConceptScore W1552004257C137183658 @default.
- W1552004257 hasConceptScore W1552004257C15152581 @default.
- W1552004257 hasConceptScore W1552004257C160539049 @default.
- W1552004257 hasConceptScore W1552004257C169760540 @default.
- W1552004257 hasConceptScore W1552004257C170493617 @default.
- W1552004257 hasConceptScore W1552004257C185856081 @default.
- W1552004257 hasConceptScore W1552004257C2777319143 @default.
- W1552004257 hasConceptScore W1552004257C2778107364 @default.
- W1552004257 hasConceptScore W1552004257C2778542668 @default.
- W1552004257 hasConceptScore W1552004257C2779134260 @default.
- W1552004257 hasConceptScore W1552004257C2779734285 @default.
- W1552004257 hasConceptScore W1552004257C40767141 @default.
- W1552004257 hasConceptScore W1552004257C513476851 @default.
- W1552004257 hasConceptScore W1552004257C55493867 @default.
- W1552004257 hasConceptScore W1552004257C71924100 @default.
- W1552004257 hasConceptScore W1552004257C86803240 @default.
- W1552004257 hasConceptScore W1552004257C92087593 @default.
- W1552004257 hasConceptScore W1552004257C98274493 @default.
- W1552004257 hasLocation W15520042571 @default.
- W1552004257 hasLocation W15520042572 @default.
- W1552004257 hasOpenAccess W1552004257 @default.
- W1552004257 hasPrimaryLocation W15520042571 @default.
- W1552004257 hasRelatedWork W148121756 @default.
- W1552004257 hasRelatedWork W1552004257 @default.
- W1552004257 hasRelatedWork W1986546861 @default.
- W1552004257 hasRelatedWork W2161356591 @default.
- W1552004257 hasRelatedWork W2616144452 @default.
- W1552004257 hasRelatedWork W3111143057 @default.
- W1552004257 hasRelatedWork W3158478053 @default.
- W1552004257 hasRelatedWork W4321332753 @default.
- W1552004257 hasRelatedWork W72019695 @default.
- W1552004257 hasRelatedWork W1521803778 @default.
- W1552004257 isParatext "false" @default.
- W1552004257 isRetracted "false" @default.
- W1552004257 magId "1552004257" @default.
- W1552004257 workType "book-chapter" @default.